AstraZeneca announced that it has successfully completed the European Union Mutual Recognition Procedure (MRP) for Symbicort? Maintenance And Reliever Therapy (Symbicort SMART?). This new asthma treatment approach allows patients to use just one inhaler for both maintenance and relief of asthma symptoms.
Results from a recent survey of European women with early breast cancer, presented for the first time at the European Society for Medical Oncology (ESMO) congress, show that the information needs of patients are not being met and that there is an unacceptably low level of patient involvement in potentially life-extending treatment decisions. The survey revealed that older women, those with a low level of education and those without Internet access are particularly uninformed.
The developmental oral therapy FTY720 (fingolimod) has demonstrated sustained benefits over two years in patients suffering from relapsing multiple sclerosis (MS), indicating that it could provide an important new option for treating this disabling neurological disease estimated to affect more than 2.5 million people worldwide.
Anti-cancer drug developer AmpliMed Corp. announced a clinical benefit rate of 44.4 percent for its lead drug candidate Amplimexon.
People suffering form rheumatoid arthritis may find their sexual activities reaching an all time low, a study finds.
A new study by researchers at the University of Helsinki, Finland, suggest that cysteine(amino acid) containing tablets and chewing gum can be a new way for the prevention of upper digestive tract cancers.
Today, the Institute of Medicine (IOM) of the National Academies released a report on the status of academic sleep research and sleep medicine in the United States. The report includes recommendations to improve public awareness and strengthen the field of sleep medicine. The project was initiated and funded by the National Institutes of Health (NIH), the American Academy of Sleep Medicine, Sleep Research Society, and the National Sleep Foundation.
According to the Arndt Schultz Law, substances vary in action depending on whether the concentration is high, medium, or low. High concentrations kill; medium concentrations suppress or inhibit; and low, or minute concentrations stimulate.
The pioneers in homeopathy were active in Norway at the end of the last century. One was O. M. Ohm (1848-1928) who, in 1892, published a small book; Practical Homeopathy For Everyone. Another pioneer was N. W. Anderschou who practiced in Oslo and, persecuted by the allopaths, moved to London.
Episodes of dangerously low blood glucose, or hypoglycemia, were greatly reduced in people who received an islet transplant for poorly controlled type 1 diabetes, according to an analysis of outcomes in 138 patients who had the procedure at 19 medical centers in the United States and Canada. This is one of the conclusions of the Collaborative Islet Transplant Registry (CITR), which tracks many factors affecting the success of this experimental procedure in people with severe type 1 diabetes.